About Us

Evogene is a leading biotechnology company for the improvement of crop productivity for the food, feed and alternative fuel industries.

Currently, the Company focuses on three key target markets:

  • Seeds – addressing essential seed traits such as: yield, environmental stresses and resistance to insects and diseases
  • Ag-Chemicals – developing novel herbicides and insecticides
  • Ag-Biologicals – developing a broad range of bio-stimulants & bio-pesticides

To reach its goals, Evogene established a unique predictive computational biology platform which relies on deep multi-disciplinary know how in biology and chemistry, combined with cutting edge computational technologies that allows the creation, integration and analysis of dedicated Big-Data for the purpose of systematic discoveries in our chosen areas of focus.

This unique technology has evolved over the last decade and has been enhanced during the years with technological advancements in Artificial Intelligence, Deep Learning and Big Data, and allows Evogene to reveal genomic sequences for seed traits, small molecules for Ag-Chemicals and various bacteria for Ag-Biologicals.

Evogene’s business model is composed of independent or collaborative R&D with advanced development and commercialization conducted by our partners. Evogene currently has strategic collaborations with world-leading agricultural companies, such as: BASF, Bayer, DuPont, ICL, Monsanto, Syngenta and more.

The Company’s headquarters are located in Rehovot, Israel and is listed for trading on the NASDAQ (NASDAQ: EVGN) and on the Tel Aviv Stock Exchange (TASE: EVGN).

    • Mr. Ofer Haviv

      Mr. Ofer Haviv

      President and Chief Executive Officer

      Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. Prior to that he held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene’s spin-off from Compugen in 2002. At Compugen, he held the position of Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ

      Mr. Haviv holds a B.A. degree in Economics and Accounting from Faculty of Management, Tel Aviv University and is a Certified Public Accountant in Israel.

      ofer.haviv@evogene.com

    • Dr. Hagai Karchi

      Dr. Hagai Karchi

      Chief Technology Officer and Head of R&D Crop Enhancement

      Dr. Karchi is co-founder of Evogene and served as its CEO from 2002 to 2004. Prior to the spin-off of Evogene from Compugen he was the Co-Head of Compugen’s Plant Genomic Division. He has over 15 years experience in the breeding of tomatoes and in molecular genomics research. His scientific achievements include the development of a molecular system for gene discovery and the development of high yielding, high quality greenhouse tomato varieties. Dr. Karchi has lectured widely in the field of plant genomics and has an extensive record of publications and patents.

      Dr. Karchi holds B.Sc and M.Sc degrees from the Hebrew University of Jerusalemױs Faculty of Agriculture, specializing in gene expression. He holds a Ph.D. from The Weizmann Institute of Science and the Hebrew University of Jerusalem, Israel.

      hagai.karchi@evogene.com

    • Mr. Ido Dor

      Mr. Ido Dor

      Executive Vice President & General Manager Crop Enhancement

      Ido was appointed as Executive Vice President & General Manager Crop Enhancement in November 2015. Mr. Dor joined Evogene in 2011 as a Director of Business Development and led the business activity of the Ag Chemicals division. Since 2015 he is leading Evogene’s Ag Biologicals activity, overseeing research, development and business aspects. Prior to joining Evogene, Ido headed the Israeli Small & Mid-Size Enterprise business activity at SAP, the world leading organizational software company. Prior to his role at SAP, Ido led a business unit at Niram Gitan Group, a leading Israeli management-consulting firm.

      Mr. Dor holds an MBA degree and a B.Sc. degree in Industrial Engineering – both from Tel Aviv University.

      Ido.dor@evogene.com

    • Mr. Eran Kosover

      Mr. Eran Kosover

      Executive Vice President & General Manager Crop Protection

      Mr. Kosover was appointed as Executive Vice President & General Manager Crop Protection in November 2015.Prior to this position, Mr. Kosover served as Evogene’s VP Project Management, where his team was in charge of managing all collaborations and internal projects in the company, and prior to that as a Business Development Manager in Evogene. Prior to Evogene, Mr. Kosover was in charge of Sales, Business Development and Operations in Atera, an Israeli Hi-tech start-up in the field of SMB IT. Prior to Atera, Mr. Kosover worked as a Project Manager in various Strategic Consulting projects for Teva Pharmaceuticals.

      Mr. Kosover holds an M.A. in Economics from the Tel Aviv University Berglas School of Economics (2006); and a B.A. in Economics and Management from the Tel Aviv University (2002).

      Eran.Kosover@evogene.com

    • Mr. Yuval Ben-Galim

      Mr. Yuval Ben-Galim

      Chief Operation Officer

      Mr. Yuval Ben-Galim joined Evogene in September 2016 as Chief Operation Officer with substantial experience in operation and R&D management positions in various high-tech companies. Prior to joining Evogene he held the role of COO at MyHeritage where he brought his significant experience in web technologies and ‘big data’ operations to spearhead the company’s new product development. Prior to that, Yuval held several senior R&D positons in various high-tech companies including mySupermarket and ProSight (owned by Oracle).

      Mr. Ben-Galim holds a B.Sc. and M.Sc. in computer science from the Hebrew University, and was the recipient of the University’s prestigious annual President’s Award in 1994.

      yuval.ben.galim@evogene.com

    • Mr. Alex Taskar

      Mr. Alex Taskar

      Chief Financial Officer

      Mr. Alex Taskar joined Evogene in January 2017 as CFO. Prior to joining Evogene Mr. Taskar served in various senior managerial positions, including CFO of Mercury Interactive Israel, CFO of Orsus Solutions and various COO and CFO positions in several Industrial and Start-up companies.

      Mr. Taskar holds an M.A. in Economics and a BA in Accounting and Economics, both from Tel-Aviv University. Mr. Taskar is also a Certified Public Accountant in Israel.

      alex.taskar@evogene.com

    • Mr. Martin Gerstel, Chairman

      Martin Gerstel is Chairman of Compugen Ltd., a publicly owned drug and diagnostic discovery company, of Keddem Bioscience, a privately owned drug discovery company and Co-Chairman of Itamar Medical, a publicly owned medical device company, all of which are headquartered in Israel. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery.

      In addition, Mr. Gerstel currently serves as a director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (“BIRD”) Foundation.

      Mr. Gerstel is a graduate of Yale University and the Stanford Graduate School of Business.

    • Mr. Ziv Kop

      Ziv Kop is the Chief Operating Officer and member of the Board of Directors of Outbrain Inc. a web-based  content discovery platform, as well as a director of Kamada Ltd (NASDAQ:KMDA).

      Previously, and since its inception in 2003 until June 2013, Mr. Kop was a Managing Partner at GlenRock Israel, a private equity investment firm, where he managed a portfolio of growth companies in the fields of advanced technologies and healthcare, and served on the board of more than ten private and public companies.

      Prior to his role at GlenRock, Mr. Kop served as Chief Executive Officer of POC Management Consulting, a leading Israeli consultancy in the field of strategic planning.

      Mr. Kop holds an LLB and MBA from Tel Aviv University Law School and Business School, and is a graduate of INSEAD’s Young Managers Program.

    • Dr. Adina Makover

      Dr. Adina Makover currently serves as Director of Life Sciences Investments at Proseed VC and is a consultant to private investors. For the past four years, Dr. Makover has been the managing director of Tzina Bio Perspective, a private investment company focusing on biotechnology and medical device ventures. Previously, she held senior management positions in biotech and device companies focusing on drugs, diagnostics and tissue engineering. Holding positions of CEO and board member, R&D, process development and production manager, Dr. Makover was responsible for both the technology and business aspects.

      Dr. Makover holds a joint PhD degree in life sciences from Columbia University (USA) and Weizmann Institute of Science (Israel) and performed post-doctoral research at the Weizmann Institute of Science. Dr. Makover also holds an MBA degree from Bar-Ilan University.

    • Mr. Leon Recanati

      Mr. Leon Recanati is the founder and CEO of GlenRock Israel, a private equity group. Mr. Recanati was Chairman and CEO of IDB Holding Corporation, one of the largest investment groups in Israel until May 2003. In addition, he served as Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Mr. Recanati was Chairman of Delek Israel Fuel Corporation and Super-Sol until 1997, in addition to several other positions in a variety of operating companies in Israel.

      Mr. Recanati’s personal involvement in organizations and diverse causes has earned him a reputation as one of Israel’s outstanding community leaders. He is Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of Tel-Aviv University’s Development Committee. He is also an active member of the Board of Governors of Tel-Aviv University and the Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency, and Chairman of Tapuah – The Israeli Society for the Advancement of the Information Age.

      Mr. Recanati received his BA and MBA degrees from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and Tel-Aviv University.

    • Dr. Kinneret Savitsky

      Dr. Kinneret Savitsky served as Chief Executive Officer at BioLineRx Ltd, a publicly traded biopharmaceutical development company, from 2009 to 2016. Previously, from 2004 to 2009, Dr. Savitsky served as the general manager of BioLine Innovations Jerusalem and was responsible for drug development acceleration and pre-clinical activities. Prior to joining BioLineRx, Dr. Savitsky served as the Vice President of Biology at Compugen Ltd. and was responsible for drug discovery and development in the company.

      Dr. Savitsky holds a Ph.D. from the Tel Aviv University. Dr. Savitsky also holds a B.Sc. in Biology from the Hebrew University of Jerusalem and a Masters degree in Human Genetics from Tel Aviv University.

    • Ms. Sarit Firon

      Ms. Sarit Firon serves as a managing partner of Cerca Partners, a venture capital investment fund, since 2016, where she previously served in the investment committee since 2014. In addition, Ms. Firon serves as chairperson of the board of directors of myThings, an ad-tech company, since 2015 and as a director in the following companies: DATORAMA, a marketing analytics company, since 2012; MediWound, a biotechnology company, since 2014; and Extreme Reality, a 3D motion capture gaming technology company, between 2014 – May 2016. Prior to that, Ms. Firon served as CEO of Extreme Reality from 2012 to 2014 and in several CFO positions since 1997 in Kenshoo, MediaMind, Olive Software, P-Cube, and RadCom.

      Ms. Firon holds a B.A. in accounting and economics from Tel-Aviv University.

    • Prof. Gad Galili

      Prof. Gad Galili is a world-renowned researcher in the field of plant genetics and a professor of genetics in the Plant Sciences Department at the Weizmann Institute of Science. A leading researcher in the field of plant metabolic pathways, he was previously a postdoctoral fellow in biology at Stanford University and in cell biology at INRA (Versailles, France). He has co-authored more than 110 publications, is a co-editor of a book entitled Seed Development and Germination and is an editorial board member of The Journal of Experimental Botany. He is the Chief Scientific Advisor on the Scientific Advisory board of Protalix, an Israeli biotechnology company that produces proteins in plant cell cultures.

      Prof. Galili holds B.Sc. and M.Sc. degrees from the Faculty of Agriculture of the Hebrew University of Jerusalem, and a Ph.D. in Plant Genetics from the Weizmann Institute of Science.

    • Prof. Avraham Levy, Chairman of the Scientific advisory board

      Prof. Avraham Levy is the Head of the Plant Science Department of the Weizmann Institute of Science in Rehovot, Israel. Prof. Levy heads a laboratory studying mechanisms that contribute to the accelerated evolution of plant genomes, such as transposons, DNA damages, DNA recombination and genome duplications. He works on wheat, Arabidopsis tomato and budding yeast. Prof. Levy is the president of the Genetic Society of Israel, he served as the chairman of the Israeli Graminae consortium and on several national and international granting agencies panels. He is an ERC fellow and has lead scientific projects as coordinator for an EU consortium and for an Israeli Center of Research Excellence.

      Prof. Levy holds a B.Sc. and an M.Sc. degree from the Faculty of Agriculture of the Hebrew University of Jerusalem and a Ph.D. from the Department of Plant Genetics of the Weizmann Institute of Science. His post-doctoral research was done at Stanford University.

    • Prof. James Birchler

      Prof. James Birchler is Curators’ Professor of Biological Science at the University of Missouri, Columbia.  He joined the University of Missouri in 1991 after serving as an associate professor at the Harvard University since 1985. Prof. Birchler lab’s research interests include gene expression in polyploids of maize, the molecular basis of aneuploid syndromes and of heterosis, the structure and behavior of chromosomes and centromeres in maize, the construction of engineered minichromosomes and in general the consequences of dosage-sensitive gene regulatory mechanisms in multicellular eukaryotes.

      Prof. Birchler received his PhD in genetics and biochemistry in 1977 from Indiana University, where he studied dosage effects on gene expression in maize. His postdoctoral work was done at Oak Ridge National Lab, Roswell Park Memorial Institute, and the University of California, Berkeley. He is a fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Sciences (USA).

    • Prof. Naama Barkai

      Prof. Naama Barkai is a professor in the departments of Molecular Genetics and Physics of Complex Systems at the Weizmann Institute of Science in Rehovot, Israel and a member of the European Molecular Biology Organization (EMBO).

      Prof. Naama Barkai received her PhD in Theoretical Physics in 1995 from the Hebrew University where she Graduated Summa Cum Laude in the studies of Statistical Mechanicsof Learning“. Her Post-Doctoral Fellow at the Physics Department, Princeton University in Princeton, New Jersey focused on Theoretical Study of Biochemical Networks.

      Prof. Barkai lab research is focused at the interface between mathematics and biology and understanding the biological constraints that are imposed on a particular system, and the impact of those constraints on the structural design of the network while developing novel solutions for fundamental biological problems such as nutrient homeostasis systems  and the organization of the cellular transcription programs.

    • Prof. Angela Sessitsch

      Dr. Angela Sessitsch heads the Bioresources Unit of the AIT Austrian Institute of Technology and is currently the President of the Austrian Association of Molecular Life Sciences and Biotechnology. The group of Dr. Sessitsch is interesting in understanding and exploring plant-associated microbiomes, primarily microbial endophytes. Her group is interested in understanding the ecology and functioning of plant microbiomes as well as to address application-relevant aspects. She has been leading national and international EU research projects and has recently initiated the EPSO Working Group on Plants and Microbiomes.

      Dr. Sessitsch holds a M.Sc. from the University of Technology, Graz, Austria and received her Ph.D. in 1997 from the Wageningen University, Netherlands. She is habilitated at the Vienna University of Natural Resources and Life Sciences. Dr. Sessitsch worked for several years with the United Nations (IAEA and FAO) before she joined AIT.

    • Dr. Hansjoerg Kraehmer

      Hansjoerg Kraehmer was born as the son of a farmer near Ulm, Germany, in 1951.

      He studied biology, chemistry and physics in Hohenheim and in Heidelberg. He received his PhD from Heidelberg University in the year 1979 and joined Schering AG in Berlin as a biologist in Research. He became department head of Herbicide Biology in the year 1986. Shortly after the formation of Hoechst-Schering Agrevo GmbH, he moved to Wilmington, DE, where he spent 2 years as Visiting Director Market Development. Back in Frankfurt, he worked for two years as a marketing manager. As a member of Aventis Crop Science GmbH, he established a robot based high throughput screening in the year 2000 together with around 20 scientists and technicians. He ended his active career within Bayer CropScience as head of Profiling and Product Support. H. Kraehmer published more than 50 papers, several book chapters and two scientific books.  He filed more than 30 patents. He was president of the European Weed Science Society between 2010 and 2012. Also, he was managing board member of the Wirtschaftsverbund Pflanzengenomforschung GABI e.V. (WPG) between 2007 and 2012. In 2015, he became member of the Editorial Board of Scientia Agriculturae Bohemica. For the last three years he worked as a consultant for different organisations.

  • As part of Evogene’s commitment to contribute to the community in which it operates, the company sees great value in its involvement and the involvement of its employees in the community, with a focus on populations in-need. In addition, as a company in the biotech industry, which requires higher scientific education, Evogene sees value in contributing the educational advancement of disadvantaged students through financial support to promote this purpose.

    Evogene’s CSR activity is focusing on three main areas:

    • Diversity in human resources
    • Academic support of disadvantaged students in the field of plant sciences
    • Social involvement in the community through volunteering activities, in which company employees take an active role

    Evogene’s past years and current CSR activities include cooperation with ‘SHEKULO TOV’ association which provides a variety of employment and leisure initiatives to hundreds of disabled people in order to facilitate their integration in the community; and with ‘MESHI’- Rehovot, a rehabilitation center which integrates people with mental disability in the labor market. The cooperation includes integration of individuals from these organizations in the company’s on-going operation.

    Furthermore, company employees are involved in volunteering activities during the Israeli holidays to collect, pack and provide food packages for populations in-need. The volunteering activities are conducted in cooperation with ‘Hod Israel’, a community charity organization, and ‘Latet’, an Israeli humanitarian aid organization.